For more information about EFFEXOR XR, you can continue to the site here.
See full Prescribing Information, including boxed warning, and Medication Guide for patients.
Important Safety Information
Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, teens, and young adults. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. EFFEXOR XR® (venlafaxine HCl) is not approved for use in children and teens.
PRISTIQ, introduced in 2008, is another product from Wyeth approved by the FDA for the treatment of major depressive disorder in adults. Find out more.
PRISTIQ® (desvenlafaxine) is approved for the treatment of major depressive disorder in adults.
Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, teens, and young adults. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. PRISTIQ is not approved for use in children under 18.
Track your symptoms, and take the results to your doctor.
View now
The goal of depression treatment is to relieve symptoms and keep them from coming back. The American Psychiatric Association (APA) describes achieving symptom relief as remission. This means feeling virtually free of symptoms of depression and getting back to doing the things you once enjoyed.
Achieving remission is important for restoring the quality of life at work and at home that you once experienced before depression. But it is also important medically: research indicates that people who have unresolved symptoms of depression after the first phase of treatment (the acute phase) may be three times as likely to experience a relapse — or have their depression return.
Unresolved symptoms can have an impact on the course of your condition. Knowing this, you shouldn't settle for some symptom relief. You deserve to reach the goal of remission.
If you're experiencing symptoms of depression, you're not alone. In a large clinical study, approximately 70% of people taking an antidepressant suffered from symptoms of depression after the first phase of treatment.
According to the APA, treatment should reduce symptoms after 4 to 8 weeks. If there is little or no response after this period, the APA then recommends reconsidering the treatment plan.
Effexor XR may be an important treatment option in the journey toward achieving remission. It is an SNRI (a serotonin-norepinephrine reuptake inhibitor) and affects two neurotransmitters in the brain thought to be important in treating depression and anxiety disorders. Effexor XR is approved by the FDA to treat depression, generalized anxiety disorder (GAD), social anxiety disorder (SAD), and panic disorder (PD) with or without agoraphobia.
In clinical studies, Effexor XR has been proven to treat depression and to help prevent it from coming back. If you are experiencing depression symptoms, you may want to talk with your doctor about the importance of achieving remission — and about Effexor XR as one treatment option that may help you reach that goal.
Learn more about the phases of treatment
Learn more about antidepressants and SNRIs
Your guide has 0 topics.
Add a topic
See your guide
Close
Fill in the information below to send an e-mail message and a link to this page.
Recipient's e-mail address
Your e-mail address
Send
This form does not collect your information. To learn more about our use of your information and your rights, please consult our Privacy Policy.
A message has been sent to your intended recipient with a link to this page. He or she will receive it shortly.
Thank you.